Measuring Pancreatic Exocrine and Endocrine Insufficiency
For exocrine insufficiency, perform a fecal elastase test on semi-solid or solid stool as your initial test, with levels <100 mg/g confirming exocrine pancreatic insufficiency (EPI); for endocrine insufficiency, use fasting glucose, HbA1c, and oral glucose tolerance test (OGTT) to detect diabetes or prediabetes. 1
Exocrine Pancreatic Insufficiency Testing
First-Line Test: Fecal Elastase-1 (FE-1)
The fecal elastase test is the most appropriate initial test for diagnosing exocrine insufficiency 1. This indirect pancreatic function test is simple, noninvasive, and relatively inexpensive 1.
Key interpretation thresholds:
- <100 mg/g of stool = good evidence of EPI 1
- 100-200 mg/g = indeterminate for EPI 1
- <50 mg/g = most reliable for severe EPI 1
Critical technical requirements:
- Must be performed on semi-solid or solid stool specimen 1
- Can be performed while patient is on pancreatic enzyme replacement therapy (PERT) 1
- Repeat measurements are not helpful for assessing treatment response 1
Alternative Tests (Rarely Needed)
Fecal fat testing:
- Rarely needed in clinical practice 1
- Must be performed on a high-fat diet 1
- Quantitative testing is generally not practical for routine use 1
- Steatorrhea is defined as coefficient of fat absorption <93% (>7% of ingested fat in stool) 1
Direct pancreatic function tests:
- Most accurate but invasive, time-consuming, and burdensome 1
- Involve stimulating the pancreas and aspirating pancreatic secretions for 30-60 minutes 1
- Analyze bicarbonate concentration and pancreatic digestive enzymes 1
- Available only at specialized centers 1
- Used more commonly for diagnosing early-stage chronic pancreatitis rather than EPI 1
Breath tests:
- Hold promise but not widely available in the United States 1
What NOT to Use
Avoid these unreliable methods:
- Response to therapeutic trial of pancreatic enzymes is unreliable for EPI diagnosis 1
- Cross-sectional imaging (CT, MRI, endoscopic ultrasound) cannot identify EPI, though they diagnose underlying pancreatic disease 1
Endocrine Pancreatic Insufficiency Testing
Standard Screening Tests
For patients without known diabetes:
- Oral glucose tolerance test (OGTT) - particularly important in specific populations 2, 3
- Fasting glucose levels 4, 3
- HbA1c 4
- Postprandial glucose 4
- HOMA-IR (homeostatic model assessment of insulin resistance) 4
Special Population: Pancreatitis Patients
Screen for diabetes within 3-6 months following acute pancreatitis, then annually thereafter 2. For chronic pancreatitis, screen annually 2.
Distinguishing features of pancreatic diabetes (type 3c):
- Concurrent pancreatic exocrine insufficiency (measure fecal elastase) 2
- Pathological pancreatic imaging findings 2
- Absence of type 1 diabetes-associated autoimmunity 2
- Loss of both insulin AND glucagon secretion 2
Special Population: Cystic Fibrosis
Annual OGTT screening beginning at age 10 years in all patients with cystic fibrosis not previously diagnosed with cystic fibrosis-related diabetes (CFRD) 2.
Important caveat: HbA1c is NOT recommended as a screening test for CFRD due to low sensitivity, though a value ≥6.5% (≥48 mmol/mol) is consistent with CFRD diagnosis 2.
Clinical Context for Testing
When to Suspect and Test
High-risk conditions requiring testing:
- Chronic pancreatitis
- Relapsing acute pancreatitis
- Pancreatic ductal adenocarcinoma
- Cystic fibrosis
- Previous pancreatic surgery 1
Moderate-risk conditions to consider:
- Duodenal diseases (celiac disease, Crohn's disease)
- Previous intestinal surgery
- Longstanding diabetes mellitus
- Hypersecretory states (Zollinger-Ellison syndrome) 1
Clinical Features Prompting Testing
Look for steatorrhea with or without diarrhea, weight loss, bloating, excessive flatulence, fat-soluble vitamin deficiencies, and protein-calorie malnutrition 1.
Common Pitfalls to Avoid
- Do not perform fecal elastase on liquid stool - requires semi-solid or solid specimen 1
- Do not use imaging alone to diagnose EPI - it cannot identify functional insufficiency 1
- Do not rely on therapeutic trials for diagnosis 1
- Do not use HbA1c alone for CFRD screening - it has low sensitivity 2
- Do not forget to screen for both exocrine AND endocrine dysfunction in pancreatic disease - they frequently coexist 2, 5